{"content":[{"text":"Media release: The Institute of Cancer Research, London","bbox":{"left":0.120984,"top":0.083595,"width":0.5116700000000001,"height":0.019584000000000004}},{"text":"Resistance-busting ICR drug enters clinical trial \n A drug discovered at The Institute of Cancer Research, London, that could \n counteract drug resistance in patients with cancers including acute myeloid \n leukaemia has entered a phase I clinical trial at The Royal Marsden NHS Foundation \n Trust.","bbox":{"left":0.120984,"top":0.114164,"width":0.7553890000000001,"height":0.11019}},{"text":"The drug, now called EP0042, is a dual inhibitor of cancer-driving proteins from the \n Aurora and Flt3 families – meaning it blocks the activity of both at once.","bbox":{"left":0.120984,"top":0.235414,"width":0.7385870000000001,"height":0.03854099999999999}},{"text":"It has shown particular promise as a potential treatment for patients with acute \n myeloid leukaemia, and could succeed in targeting FLT3-mutated cancers that \n become resistant to current FLT3-selective inhibitor drugs.","bbox":{"left":0.120984,"top":0.285015,"width":0.699392,"height":0.05739099999999997}},{"text":"It has also shown potential as a future treatment for other cancers including the \n childhood cancer neuroblastoma.","bbox":{"left":0.120984,"top":0.353466,"width":0.704434,"height":0.03854099999999999}},{"text":"The opening of the clinical trial represents a major milestone in a long-running \n programme of Institute of Cancer Research (ICR)-led drug discovery and \n development research, ultimately in collaboration with the international, oncology \n focussed drug development company, Ellipses Pharma.","bbox":{"left":0.120984,"top":0.403067,"width":0.7195290000000001,"height":0.07616899999999999}},{"text":"Ellipses Pharma has rapidly progressed the development of EP0042 following \n successful negotiations between the ICR and the company, which were led by our \n Business and Innovation Office.","bbox":{"left":0.120984,"top":0.490296,"width":0.730847,"height":0.05737900000000001}},{"text":"Under the terms of the deal between the ICR and Ellipses Pharma, the company \n took full responsibility for the development programme including additional pre- \n clinical studies and reformulation of the drug product to obtain a clinical trial \n authorisation, progression into the clinic for the first-in-human clinical trial, and any \n further clinical studies needed.","bbox":{"left":0.120984,"top":0.558735,"width":0.732812,"height":0.09498300000000004}},{"text":"EP0042 was originally discovered in a project led by Spiros Linardopoulos, former \n Team Leader in Target Drug Discovery in the ICR’s Cancer Therapeutics and Breast \n Cancer Research Divisions.","bbox":{"left":0.120984,"top":0.664921,"width":0.75385,"height":0.05721200000000004}},{"text":"The drug has now entered a phase I trial with study centres planned in the UK, the \n Netherlands and Australia. If the phase I trial is successful, the drug could go on to \n larger trials and ultimately become a new treatment for cancers including acute \n myeloid leukaemia and neuroblastoma.","bbox":{"left":0.120984,"top":0.733371,"width":0.734714,"height":0.07616900000000004}},{"text":"Dr David Taussig, Consultant Haematologist at The Royal Marsden and \n Honorary Team Leader in Acute Leukaemia at the ICR, is the global co- \n ordinating investigator on the study. He said:","bbox":{"left":0.120984,"top":0.820672,"width":0.681462,"height":0.05739799999999995}}],"images_bbox":[],"images_bbox_not_text_overlap":[]}